Distalgesic: Important Safety Warning
Distalgesic is a discontinued combination analgesic containing dextropropoxyphene (propoxyphene) 32.5 mg and paracetamol (acetaminophen) 325 mg per tablet that was withdrawn from most markets due to serious safety concerns, including rapid-onset fatal overdoses and cardiac toxicity.
What Distalgesic Was
Distalgesic was a WHO Step II analgesic (for mild to moderate pain) combining:
- Dextropropoxyphene hydrochloride 32.5 mg (a weak opioid)
- Paracetamol 325 mg (a non-opioid analgesic)
Why It Was Withdrawn
Fatal overdose risk: Death characteristically occurred rapidly—as little as 1 hour after ingestion and usually before hospital treatment could be initiated 1. The fatal dose could be as small as 15 tablets or possibly less 1. Convulsions and respiratory failure preceded death, with toxicity significantly increased by alcohol 1.
Addiction liability: Evidence suggested liability to dependence or even addiction with dextropropoxyphene 1.
Current Guideline-Recommended Alternatives
For mild to moderate pain (WHO Step II), current ESMO guidelines recommend 2:
First-Line Combination Therapy
- Paracetamol 500-1000 mg (maximum 4-6 g daily) PLUS
- Weak opioids in combination:
Alternative Approach
- Low doses of strong opioids (morphine, oxycodone) in combination with non-opioid analgesics 2
Specific Dosing for Oxycodone-Acetaminophen
- Oxycodone 5-15 mg with acetaminophen every 4-6 hours 4
- Note: Acetaminophen component now limited to ≤325 mg per tablet 4
Evidence-Based Comparison
Dihydrocodeine showed superior efficacy to dextropropoxyphene/paracetamol combinations: After 2 weeks' treatment, controlled-release dihydrocodeine provided statistically significantly less severe pain on passive movement (p=0.02) compared to dextropropoxyphene/paracetamol, with no difference in side-effects by study end 6. Dihydrocodeine also offers the advantage of twice-daily versus 3-4 times daily dosing 6.
Critical Prescribing Principles
For chronic pain 2:
- Prescribe analgesics on a regular schedule, not "as required"
- Provide rescue doses (10-15% of total daily dose) for breakthrough pain
- If >4 breakthrough doses needed daily, increase baseline therapy
Mandatory co-prescribing with opioids 2:
- Laxatives must be routinely prescribed for prophylaxis and management of opioid-induced constipation
- Antiemetics (metoclopramide, antidopaminergic drugs) for opioid-related nausea/vomiting
Special Populations
Renal impairment: All opioids should be used with caution at reduced doses and frequency 2. For chronic kidney disease stages 4-5 (eGFR <30 mL/min), fentanyl and buprenorphine (transdermal or IV) are the safest choices 2.
Paracetamol maximum dosing: 4-6 g daily in normal patients 3, 7, 5; dose reduction recommended in liver disease or malnourished patients 8.
Common Pitfall to Avoid
Do not use dextropropoxyphene/propoxyphene if somehow still available—it has been removed from guidelines due to unfavorable risk-benefit profile, particularly the rapid-onset fatal overdose risk that occurs before medical intervention is possible 1.